Understanding the Versatile Roles and Applications of EpCAM in Cancers: from Bench to Bedside

Overview

Journal Exp Hematol Oncol

Publisher Biomed Central

Specialty Hematology

Date 2022 Nov 11

PMID 36369033

Authors

Yiyang Liu

Yufei Wang

Sheng Sun

Zeyu Chen

Shuai Xiang

Zeyang Ding

Zhao Huang

Bixiang Zhang

Affiliations

Soon will be listed here.

Abstract

Epithelial cell adhesion molecule (EpCAM) functions not only in physiological processes but also participates in the development and progression of cancer. In recent decades, extensive efforts have been made to decipher the role of EpCAM in cancers. Great advances have been achieved in elucidating its structure, molecular functions, pathophysiological mechanisms, and clinical applications. Beyond its well-recognized role as a biomarker of cancer stem cells (CSCs) or circulating tumor cells (CTCs), EpCAM exhibits novel and promising value in targeted therapy. At the same time, the roles of EpCAM in cancer progression are found to be highly context-dependent and even contradictory in some cases. The versatile functional modules of EpCAM and its communication with other signaling pathways complicate the study of this molecule. In this review, we start from the structure of EpCAM and focus on communication with other signaling pathways. The impacts on the biology of cancers and the up-to-date clinical applications of EpCAM are also introduced and summarized, aiming to shed light on the translational prospects of EpCAM.

Citing Articles

Biological roles and clinical applications of EpCAM in HCC.

Liu P, Zhang Q, Liu F Discov Oncol. 2025; 16(1):319.

PMID: 40087210 DOI: 10.1007/s12672-025-02095-0.

Multifaceted Approaches in Epithelial Cell Adhesion Molecule-Mediated Circulating Tumor Cell Isolation.

Szerenyi D, Jarvas G, Guttman A Molecules. 2025; 30(5).

PMID: 40076201 PMC: 11901967. DOI: 10.3390/molecules30050976.

Harnessing the power of traceable system C-GAP: homologous-targeting to fire up T-cell immune responses with low-dose irradiation.

Zhuang W, Pan K, Wu J, Liu L, Lv S, Hu J J Nanobiotechnology. 2025; 23(1):207.

PMID: 40075499 PMC: 11905511. DOI: 10.1186/s12951-025-03281-6.

Advances in magnetic affinity-based isolation/detection of exosomes for robust diagnostics.

Solovicova V, datkova A, Bertok T, Kasak P, Vikartovska A, Lorencova L Mikrochim Acta. 2025; 192(4):206.

PMID: 40042696 PMC: 11882713. DOI: 10.1007/s00604-025-07048-6.

New insights into Notch signaling as a crucial pathway of pancreatic cancer stem cell behavior by chrysin-polylactic acid-based nanocomposite.

Ragab E, El Gamal D, El-Najjar F, Elkomy H, Ragab M, Elantary M Discov Oncol. 2025; 16(1):107.

PMID: 39891818 PMC: 11787125. DOI: 10.1007/s12672-025-01846-3.

References

Fiorillo M, Scatena C, Naccarato A, Sotgia F, Lisanti M . Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase. Cell Death Differ. 2021; 28(9):2797-2817. PMC: 8408289. DOI: 10.1038/s41418-021-00788-x. View

Wen K, Sung P, Chou Y, Pan C, Wang P, Lee O . The role of EpCAM in tumor progression and the clinical prognosis of endometrial carcinoma. Gynecol Oncol. 2017; 148(2):383-392. DOI: 10.1016/j.ygyno.2017.11.033. View

Wang M, Sun R, Zhou X, Zhang M, Lu J, Yang Y . Epithelial cell adhesion molecule overexpression regulates epithelial-mesenchymal transition, stemness and metastasis of nasopharyngeal carcinoma cells via the PTEN/AKT/mTOR pathway. Cell Death Dis. 2018; 9(1):2. PMC: 5849035. DOI: 10.1038/s41419-017-0013-8. View

Oberneder R, Weckermann D, Ebner B, Quadt C, Kirchinger P, Raum T . A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. Eur J Cancer. 2006; 42(15):2530-8. DOI: 10.1016/j.ejca.2006.05.029. View

Barth A, Kim H, Riedel-Kruse I . Regulation of epithelial migration by epithelial cell adhesion molecule requires its Claudin-7 interaction domain. PLoS One. 2018; 13(10):e0204957. PMC: 6179577. DOI: 10.1371/journal.pone.0204957. View

Rhee H, Nahm J, Kim H, Choi G, Yoo J, Lee H . Poor outcome of hepatocellular carcinoma with stemness marker under hypoxia: resistance to transarterial chemoembolization. Mod Pathol. 2016; 29(9):1038-49. DOI: 10.1038/modpathol.2016.111. View

Ng V, Ang S, Chan J, Choo A . Characterization of epithelial cell adhesion molecule as a surface marker on undifferentiated human embryonic stem cells. Stem Cells. 2009; 28(1):29-35. DOI: 10.1002/stem.221. View

Macdonald J, Henri J, Roy K, Hays E, Bauer M, Veedu R . EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs. Cancers (Basel). 2018; 10(1). PMC: 5789369. DOI: 10.3390/cancers10010019. View

Trerotola M, Guerra E, Ali Z, Aloisi A, Ceci M, Simeone P . Trop-2 cleavage by ADAM10 is an activator switch for cancer growth and metastasis. Neoplasia. 2021; 23(4):415-428. PMC: 8042651. DOI: 10.1016/j.neo.2021.03.006. View

10.

Ding J, Zhou X, Zou H, Wu J . Hedgehog signaling pathway affects the sensitivity of hepatoma cells to drug therapy through the ABCC1 transporter. Lab Invest. 2017; 97(7):819-832. DOI: 10.1038/labinvest.2017.34. View

11.

Zhou Y, Mohamadi R, Poudineh M, Kermanshah L, Ahmed S, Saberi Safaei T . Interrogating Circulating Microsomes and Exosomes Using Metal Nanoparticles. Small. 2015; 12(6):727-32. DOI: 10.1002/smll.201502365. View

12.

Lian S, Xie R, Ye Y, Xie X, Li S, Lu Y . Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release. EBioMedicine. 2019; 42:281-295. PMC: 6491392. DOI: 10.1016/j.ebiom.2019.03.018. View

13.

Zhang M, Zhao Z, Pritykin Y, Hannum M, Scott A, Kuo F . Ectopic activation of the miR-200c-EpCAM axis enhances antitumor T cell responses in models of adoptive cell therapy. Sci Transl Med. 2021; 13(611):eabg4328. PMC: 9374309. DOI: 10.1126/scitranslmed.abg4328. View

14.

Vallera D, Zhang B, Gleason M, Oh S, Weiner L, Kaufman D . Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells. Cancer Biother Radiopharm. 2013; 28(4):274-82. PMC: 4209492. DOI: 10.1089/cbr.2012.1329. View

15.

Herlyn D, Herlyn M, Ross A, Ernst C, Atkinson B, KOPROWSKI H . Efficient selection of human tumor growth-inhibiting monoclonal antibodies. J Immunol Methods. 1984; 73(1):157-67. DOI: 10.1016/0022-1759(84)90041-3. View

16.

Han J, Won M, Kim J, Jung E, Min K, Jangili P . Cancer stem cell-targeted bio-imaging and chemotherapeutic perspective. Chem Soc Rev. 2020; 49(22):7856-7878. DOI: 10.1039/d0cs00379d. View

17.

Munz M, Murr A, Kvesic M, Rau D, Mangold S, Pflanz S . Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. Cancer Cell Int. 2010; 10:44. PMC: 2989956. DOI: 10.1186/1475-2867-10-44. View

18.

Pan M, Schinke H, Luxenburger E, Kranz G, Shakhtour J, Libl D . EpCAM ectodomain EpEX is a ligand of EGFR that counteracts EGF-mediated epithelial-mesenchymal transition through modulation of phospho-ERK1/2 in head and neck cancers. PLoS Biol. 2018; 16(9):e2006624. PMC: 6177200. DOI: 10.1371/journal.pbio.2006624. View

19.

Kumar Katakam S, Tria V, Sim W, Yip G, Molgora S, Karnavas T . The heparan sulfate proteoglycan syndecan-1 regulates colon cancer stem cell function via a focal adhesion kinase-Wnt signaling axis. FEBS J. 2020; 288(2):486-506. DOI: 10.1111/febs.15356. View

20.

Liu X, Deng J, Yuan Y, Chen W, Sun W, Wang Y . Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer. Pharmacol Ther. 2022; 239:108296. DOI: 10.1016/j.pharmthera.2022.108296. View